Truist Securities analyst Srikripa Devarakonda initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage